SynthesisFrontiers in oncology2024
Prognostic role of platelet-to-lymphocyte ratio in patients with rectal cancer undergoing resection: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Prognostic Significance of Platelet-to-Lymphocyte Ratio and Lymphocyte-to-Monocyte in Colorectal Cancer: a Meta-Analysis.Journal of gastrointestinal cancer · 2025Pooled it
- Significant Correlation of Dynamic Pan-Immune Inflammation Value and Magnetic Resonance Imaging Response in Patients with Locally Advanced Rectal Cancer Treated with Total Neoadjuvant Therapy.Current oncology (Toronto, Ont.) · 2026Article
- Beyond PSA-Can Systemic Inflammatory Indices Improve Prostate Cancer Detection?Medical sciences (Basel, Switzerland) · 2026Observational
- Combination of Naples prognostic score and pathological factors for evaluating the long-term prognosis of patients with late-onset colorectal cancer: a multicenter machine learning study.Translational cancer research · 2025Article
- Colorectal Cancer-One Disease, Two Fires: Distinct Inflammatory Landscapes in Colon and Rectal Cancer.Diagnostics (Basel, Switzerland) · 2025Article
- Metabolic and proteomic signatures differentiate inflammatory phenotypes from cancer and predict treatment response in patient sera.Bioengineering & translational medicine · 2025Article
- Comparative Prognostic Role of PLR and NLR in Colon Cancer: A Retrospective Analysis of Preoperative Inflammatory Markers.Medicina (Kaunas, Lithuania) · 2025Observational
- From Blood to Outcome: Inflammatory Biomarkers in Rectal Cancer Surgery at a Romanian Tertiary Hospital.Diseases (Basel, Switzerland) · 2025Article
- Comparison of the clinical significance of lymphocyte-based inflammatory indices between the two major subtypes of primary aldosteronism.Endocrine · 2025Article
- Prognostic value of inflammatory markers and different treatment regimens in neuroendocrine cervical carcinoma: a retrospective study.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammation plays a pivotal role in tumor growth, with the platelet-to-lymphocyte ratio (PLR) emerging as a promising serum biomarker for prognostic assessment in patients with cancer. However, its specific role in rectal cancer remains controversial. Methods: A comprehensive literature review encompassing PubMed, EMBASE, and the Cochrane Library, spanning from their inception to March 2024, was conducted. The systematic review and meta-analysis strictly adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines (PRISMA). Quality assessment was conducted using the Newcastle-Ottawa scale (NOS). This study aimed to assess the available literature on the association of PLR with both overall survival (OS) and disease-free survival (DFS) in patients with rectal cancer undergoing resection. Results: Twenty-three observational studies, encompassing 7577 patients, were included in the analysis. These comprised 20 retrospective and 3 prospective cohort studies, with NOS scores ranging from 5 to 8. A significant association was found between high PLR and worse OS (hazard ratio [HR] 1.00; 95% confidence interval [CI] 1.00-1.01; P = 0.01). Conversely, no significant association was observed between PLR and DFS (HR 1.14; 95% CI 0.98-1.32; P = 0.09). Conclusions: PLR serves as an independent clinical predictor of OS in patients with rectal cancer treated with curative surgery, but not of DFS. This easily accessible biomarker appears to be an optimal prognostic index and may aid clinicians in predicting the prognosis of rectal cancer, facilitating the development of individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.